- Home
- CIFR vs IBRX Comparison
CIFR vs IBRX Comparison
Compare CIFR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | IBRX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CIFR | IBRX |
|---|---|---|
| Price | $23.67 | $7.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $24.91 | $12.57 |
| AVG Volume (30 Days) | ★ 22.6M | 12.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $12.29 | $88.59 |
| Revenue Next Year | $240.53 | $131.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $3.08 | $1.95 |
| 52 Week High | $25.56 | $12.43 |
Technical Indicators
Market Signals| Indicator | CIFR | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 45.58 |
| Support Level | $12.97 | $6.64 |
| Resistance Level | $25.52 | $8.54 |
| Average True Range (ATR) | 1.86 | 0.56 |
| MACD | 0.31 | -0.05 |
| Stochastic Oscillator | 76.01 | 15.93 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.